Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
TTEC Digital has introduced AI Gateway, a software solution that enables enterprises to integrate modern AI capabilities with existing contact center technology without costly system overhauls. The platform supports connections with leading AI providers and CX systems, allowing clients to deploy, test, and scale AI flexibly, resulting in early repo…
Commercial Vehicle Group (CVGI) has completed a sale-leaseback transaction for its Vonore, Tennessee manufacturing facility, generating $16 million in proceeds. The company used the funds to prepay part of its term loan, lowering its leverage. CVG will lease back the property for 20 years with a $1.4 million annual base rent initially. The transact…
Roadzen Inc., a Nasdaq-listed AI company integrating insurance and mobility solutions, announced it will present at the 'Powering the AI Revolution' virtual conference hosted by Maxim Group. The presentation will highlight Roadzen’s AI-driven technology that enhances safety, reduces claims costs, and improves underwriting across international marke…
Diginex Limited appoints Jacob Friedman as Chief Operating Officer and Sandra Kovacheva as Chief Administrative Officer to accelerate the integration of its four operating entities into a unified global platform. These leadership enhancements aim to boost operational efficiency, governance, and compliance as Diginex advances its strategy to deliver…
TransUnion introduced TruIQ Credit Strategy Studio, a self-service platform that drastically reduces prescreen campaign build times for lenders by up to 75%. The tool features no-code, drag-and-drop capabilities, real-time collaboration, and interactive dashboards, streamlining campaign development and enabling faster market responsiveness. Integra…
MiNK Therapeutics disclosed that its investigational allogeneic iNKT cell therapy, agenT-797, will be featured at the ASGCT 2026 meeting. The therapy harnesses innate and adaptive immunity to target cancer, immune-mediated diseases, and severe pulmonary inflammation. The presentation underscores agenT-797's potential to modulate adaptive immune res…
Context Therapeutics announced that the FDA has granted Fast Track Designation to its investigational drug CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, aimed at treating platinum-resistant ovarian cancer. The company is conducting a Phase 1 clinical trial with interim data expected in June 2026. This designation could expedite the de…
Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a reimbursement coverage agreement with Highmark for its CNSide CSF Tumor Cell Enumeration assay, increasing total covered lives from approximately 67 million to 75 million. This expands patient access and supports broader adoption of CNSide in the detection and monitoring of met…
Annovis Bio announced it received a U.S. patent covering the use of its investigational drug buntanetap in preventing and treating neurological injuries caused by brain infections, including those linked to Alzheimer's disease. The patent extends through 2044 and covers both preventive and therapeutic applications against a range of infectious agen…
Cartesian Therapeutics announced inducement stock option grants to two new employees, totaling 52,450 shares at an exercise price of $6.39 per share. The options vest over four years with a ten-year term, granted to attract talent under Nasdaq inducement rules. Cartesian is advancing its lead CAR-T therapy, Descartes-08, in clinical trials for auto…
Microchip Technology has been certified by UL Solutions to the IEC 62443-4-1 Maturity Level 2 standard, confirming its secure development lifecycle for industrial automation and control system products. This certification demonstrates the company's capability in providing secure-by-design hardware and software, helping customers reduce supply chain…
Adagene Inc., a clinical-stage biotech company specializing in novel antibody-based cancer immunotherapies, announced the pricing of an underwritten public offering of 18.67 million ADSs at $3.75 each, raising gross proceeds of approximately $70 million. The offering attracted participation from both new and existing institutional investors and is …
Oportun Financial Corporation announced that Kate Layton and Gaurav Rana will serve as interim co-CEOs following the departure of CEO Raul Vazquez. Both executives will retain their current roles while leading the company during the CEO search. Vazquez will continue as an advisor until July 2026 to facilitate a smooth transition. The board is activ…
AirSculpt Technologies, a US-based provider of body contouring procedures, reported its fourth quarter and full year 2025 financial results. The company saw a decline in case volume and revenue compared to 2024 but delivered improved adjusted EBITDA and reduced net losses in Q4. The company implemented new strategies and procedures during 2025, lea…
Freight Technologies announced significant progress in transforming into a software-first, AI-native logistics technology company, focusing on scaling its AI-powered platforms like Fleet Rocket, Zayren, and Fr8Radar. The company is exploring strategic alternatives for its traditional brokerage operations to concentrate resources on its AI software …
Scorpio Tankers Inc. has entered into a strategic collaboration with AMPERA, Inc. to jointly develop and commercialize advanced micronuclear power solutions aimed at powering maritime vessels, offshore, and port infrastructure with zero carbon emissions. The collaboration focuses on deploying ultra-safe micro nuclear reactors, including floating nu…
Transocean Ltd. announced $1 billion in new and extended offshore drilling contracts spanning Norway and Brazil, along with the early retirement of $358 million in senior secured notes. These developments strengthen the company's backlog, reduce interest expenses, and support its deleveraging strategy.
Burning Rock Biotech Limited announced that founder, chairman, and CEO Yusheng Han purchased 31,487 American Depositary Shares (ADSs) for $546,603.90 on the open market, adding to prior purchases this year. These transactions signal strong insider confidence in the company's precision oncology business, which focuses on next generation sequencing (…
Global Net Lease, Inc. announced that board members Sue Perrotty and Governor Edward Rendell will retire following the 2026 Annual Meeting of Stockholders, reducing the board size to eight members. The company acknowledges their contributions, particularly during the 2023 merger and internalization process.
Acuity Inc. delivered a robust second-quarter fiscal 2026 performance marked by 5% net sales growth to $1.1 billion, 21% increase in operating profit to $133 million, and a 26% rise in diluted EPS to $3.09. The company's two business segments had mixed results: Acuity Brands Lighting sales slightly declined by 2.8%, while Acuity Intelligent Spaces …
Roivant Sciences announced the expansion of its brepocitinib development program to include a new seamless Phase 2b/3 clinical trial for the inflammatory scalp disorder lichen planopilaris (LPP), which currently has no FDA-approved treatments. Concurrently, Roivant reported topline results from Immunovant's Phase 3 studies of batoclimab in thyroid …
Priovant Therapeutics announced the initiation of a seamless Phase 2b/3 clinical trial for brepocitinib in treating Lichen Planopilaris (LPP), a severe inflammatory scalp disorder with no FDA-approved treatments. This marks the fourth indication in brepocitinib's late-stage development alongside dermatomyositis, non-infectious uveitis, and cutaneou…
Futu Holdings Limited, a Nasdaq-listed online brokerage and wealth management platform, declared a cash dividend of $0.325 per ordinary share (equivalent to $2.6 per American Depositary Share), totaling approximately $365 million, payable to shareholders as of April 16, 2026, with payment expected around April 29, 2026.
Immunovant announced that its Phase 3 clinical trials for batoclimab in treating thyroid eye disease (TED) failed to meet their primary efficacy endpoint. While safety profiles were consistent with previous results and no new risks identified, the drug did not achieve the targeted proptosis improvement at 24 weeks. The company highlighted promising…
Celldex Therapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering of 10,345,000 shares at $29.00 per share, expecting gross proceeds of approximately $300 million. The offering aims to fund its commercial readiness and potential launch of barzolvolimab for chronic spontaneous urticaria, continue …
